A new peptide developed by researchers in Temple University’s College of Science and Technology has demonstrated efficacy against triple negative breast cancer.
The leptin receptor antagonist peptide, developed by researchers Laszlo Otvos and Eva …
Separate studies published online on February 21 in the Journal of Experimental Medicine (www.jem.org) identify a protein that drives tumor-promoting inflammation in pancreatic and breast tumors.
Inflammatory reactions come in several flavors –…
The most common type of breast cancer in older women — estrogen and progesterone receptor (ER/PR) positive breast cancer — has been linked to a protein that fends off aging-related cellular damage.
A new study led by Vanderbilt-Ingram Cancer…
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) …
PHILADELPHIA — Young mice that experienced the psychosocial stress of prolonged separation from their mothers had a higher incidence and faster onset of breast tumors compared with young mice who did not experience this stressful life event. Spec…
Researchers from Mount Sinai School of Medicine have developed a new computational method that will help streamline the analysis of gene expression experiments and provide scientists with a better mechanistic understanding of the differences between…
Regular use of ibuprofen and aspirin inhibits the formation and growth of breast cancer, according to data published in the Proceedings for the 94th Annual Meeting of the American Association for Cancer Research (AACR). The data, taken from the National Cancer Institute?s (NCI) Women?s Health Initiative (WHI) Observational Study, concluded that weekly doses of non-steroidal anti-inflammatory drugs (NSAIDs) had a significant effect in reducing the risk of breast cancer.
?These results suggest that even women at high risk for breast cancer may be protected by taking NSAIDs,? explains Randall Harris, M.D., Ph.D., lead investigator of the study, professor of the division of epidemiology and biometrics at the Ohio State University. ?However, before usage guidelines for NSAIDs can be implemented, additional studies are needed.?
Until now, researchers thought that breast cancer nearly always began when cells in the epithelium went haywire. But new research suggests that genetic mutations can ? and do ? occur initially in a deeper layer of breast tissue, called the stroma. This presents a serious concern for physicians, who believed that breast tumors spread from epithelial tissue. “Genetic alterations in carcinomas, including breast cancers, have always been attributed to epithelial cells,” said Charis Eng, Klotz professor and director of the Clinical Cancer Genetics Program at Ohio State University. She co-authored a new study that looks at genetic mutations in breast tissue.